Drug Shortages: 10 Ethics Rules for Hospitals
Finally, Rosoff says, in the rare events in which two clinically equivalent patients need a drug for which supply is only sufficient for one, "a coin will be tossed to choose between them."
The issue is increasingly a controversial one because of unpredictable shortages, especially involving expensive drugs that sometimes find their way into other routes of sale, the so-called grey market. Sometimes raw materials are contaminated, or there are quality issues with the manufacturing process, or the manufacturer just decides to discontinue production.
In an accompanying editorial, Paula Rochon, MD, and Jerry Gurwitz, MD, of the Women's College Research Institute in Toronto say Rosoff and his colleagues "serves as a wake-up call to clinicians to become better educated about and more engaged in the issue of drug shortages.
"Clinicians need to be vigilant about reviewing the drug shortage alert they receive because these alerts may directly affect their patients and their plans for patient care," they wrote.
Cheryl Clark is senior quality editor and California correspondent for HealthLeaders Media. She is a member of the Association of Health Care Journalists.
- As Retail Clinics Surge, Quality Metrics MIA
- No Employee Satisfaction, No Patient-Centered Culture
- Providers' Push to Consolidate Roils Payers
- RN Named Chief Patient Experience Officer
- Medicare Cost, Quality Data Tools Weak, Says GAO
- Population Health Pays Off for NY Collaborative
- Former NQF Co-Chair Linked to Conflicts of Interest in Journal Probe
- How Payers Are Curbing Behavioral-Health Cost Drivers
- How Simple Data Analytics is Driving Physician Incentives
- AMA Pushes Lame Duck Congress for SGR Repeal